Kolkata: The Kolkata Gynaecological Oncology Trials and Translational Research Group received ICMR funding for the clinical trial of a PARP inhibitor, a costly anti-cancer drug for targeted therapy involving mutations in the BRCA gene. The clinical trial will involve 350 patients suffering from cervical cancer, the second leading cancer among women.
Launched on Friday at the 8th annual meet organised by KOLGOTRG, the trial will focus on providing the right dose of PARP inhibitor with lower side effects and at a lower cost, to the right patients.
The role of PARP inhibitors is to prevent cancer cells from repairing their DNA. "I am thankful to ICMR for funding this initiative," said cancer research scientist Asima Mukhopadhyay, director, KOLGOTRG.
Funded by ICMR and facilitated by Suraksha Diagnostics Limited, this trial will be open across all states in India and some sites abroad.